BioWick SureLock Clinical Outcomes Study

Back to results

Primary Purpose

Status

Completed

Phase

Not Applicable

Locations

United States

Study Type

Interventional

Intervention

BioWick SureLock Implant

About this trial

This is an interventional treatment trial for Rotator Cuff Tear

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

Clinical diagnosis of rotator cuff tear which is greater than or equal to 1.5 cm and less than or equal to 4.0 cm full thickness of either the supraspinatus or infraspinatus determined by MRI which has not been previously repaired;
Goutallier Stage 2 or less;
Patte Stage II (mid humeral head retraction);
Tear(s) confirmed intra-operatively by calibrated probe, tears measured in both anterior-posterior and medial-lateral planes;
Subject is skeletally mature at the surgical site;
Subject is able to read and understand the ICF and has voluntarily provided written informed consent.

Exclusion Criteria:

Clinical diagnosis of a rotator cuff tear of the subscapularis that requires repair (not including debridement);
Conditions which, in the opinion of the Principal Investigator, may limit the subject's ability or willingness to follow postoperative care or study instructions;
If female, subject is pregnant;
Presence of local or systemic infection;
Suprascapular nerve compression requiring release or documented by EMG-NCV;
Substance abuse, including tobacco, alcohol, or illicit drugs which, in the investigator's judgment, could impair healing or influence study compliance;
Foreign body sensitivity. If material sensitivity is suspected, testing should be completed prior to device implantation;
Insufficient blood supply or previous infection which may hinder the healing process;
Subject conditions including: insufficient quantity or quality of bone or soft tissue, or immature bone where the device may impact or disrupt the growth plate;
Subject is a prisoner or member of another vulnerable population;
Cortisone injection within 6 weeks prior to surgical treatment;
Use of immune suppressants or chemotherapeutic medications within the last 12 months;
Use of systemic corticosteroids at any daily dose for more than 1 month within the last 12 months.

Sites / Locations

The Orthopaedic Clinic Association
Eisenhower Medical Center
Orthopaedic Medical Group of Tampa Bay PA
Foundation for Orthopaedic Research and Eduation
Norton Orthopaedics and Sports Medicine
University of Utah
University of Virginia

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

BioWick SureLock Implant

Arm Description

All subjects are part of a single arm. All subjects received the BioWick SureLock implant.

Outcomes

Primary Outcome Measures

Number of Participants Not Requiring Removal or Reoperation of the Implant

The primary endpoint of this study is survivorship (lack of reoperation/device removal) at 12 months postoperative. Implant survivorship for each subject was determined by whether the subject underwent a revision or reoperation of the study device. Survivorship was assessed using a Kaplan-Meier analysis. Possible scores range from 0% (lowest survivorship) to 100% (highest survivorship).

Secondary Outcome Measures

Number of Participants Not Requiring Removal or Reoperation of the Implant

Implant survivorship (lack of reoperation/device removal) at 3 months and 6 months postoperative. Implant survivorship for each subject was determined by whether the subject underwent a revision or reoperation of the study device. Survivorship was assessed using a Kaplan-Meier analysis. Possible scores range from 0% (lowest survivorship) to 100% (highest survivorship).

American Shoulder and Elbow Surgeons (ASES) Patient Self-Evaluation Score

Pain and function as measured by the American Society of Shoulder and Elbow Surgeons (ASES) questionnaire. ASES consists of 3 subcomponent scores including pain, instability, and activities of daily living. The pain score can be 0 to 10 with 0 being no pain and 10 being the worst pain imaginable. The instability score can be 0 to 10 with 0 being no instability and 10 being the worst instability imaginable. The activities of daily living consists of 10 questions with ordinal responses of 0, 1, 2, and 3 with 3 involving no limitation and 0 is unable to do. The 3 subcomponents combine to make the overall ASES score which can range from 0 to 100 with 0 being the worst possible score and 100 being the best.

Visual Analogue Scale (VAS) Pain Score

A Visual Analogue Scale (VAS) is a measurement instrument that tries to measure a characteristic or attitude that is believed to range across a continuum of values and cannot easily be directly measured. It is often used in epidemiologic and clinical research to measure the intensity or frequency of various symptoms. Possible scores range from 0 (no pain) to 10 (very much pain).

The Veterans RAND 12 (VR-12) Item Health Survey Physical Score

A brief, generic, multi-use, self-administered health survey comprised of 12 items. The instruments are primarily used to measure health-related quality of life, to estimate disease burden, and to evaluate the disease-specific impact on general and selected populations. A higher VR-12 score indicates better health (0-100 scale).

The Veterans RAND 12 (VR-12) Item Health Survey Mental Score

A brief, generic, multi-use, self-administered health survey comprised of 12 items. The instruments are primarily used to measure health-related quality of life, to estimate disease burden, and to evaluate the disease-specific impact on general and selected populations. A higher VR-12 score indicates better health (0-100 scale).

Range of Motion (ROM) - Active Forward Elevation

Range of motion (ROM): The full movement potential of a joint, usually its range of flexion and extension. Normal range for active forward elevation is 150-180 degrees.

Device Safety

Safety evaluations were based on the frequency and incidence of device-related adverse events. Device-related adverse events included all reported adverse events classified as "Definitely" or "Possibly" related to the device. Adverse event data were collected throughout the entire duration of the study from enrollment thru subject completion. Routine collection occurred at each visit (3 months, 6 months, and 1 year). Additional details of reports of adverse events can be found in the Adverse Events section of the posted results.

Full Information

NCT ID

NCT03199391

First Posted

June 22, 2017

Last Updated

June 16, 2022

Sponsor

Zimmer Biomet

1. Study Identification

Unique Protocol Identification Number

NCT03199391

Brief Title

BioWick SureLock Clinical Outcomes Study

Official Title

Efficacy of the BioWick SureLock Implant for the Reattachment of Soft Tissue to Bone in Subjects Undergoing Rotator Cuff Repairs

Study Type

Interventional

2. Study Status

Record Verification Date

June 2022

Overall Recruitment Status

Completed

Study Start Date

April 26, 2017 (Actual)

Primary Completion Date

May 5, 2021 (Actual)

Study Completion Date

May 5, 2021 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title

Sponsor

Name of the Sponsor

Zimmer Biomet

4. Oversight

Studies a U.S. FDA-regulated Drug Product

No

Studies a U.S. FDA-regulated Device Product

Yes

Product Manufactured in and Exported from the U.S.

Yes

Data Monitoring Committee

No

5. Study Description

Brief Summary

The purpose of this study is to collect postmarket data in subjects who receive surgical treatment of a full-thickness rotator cuff tear (of at least 1.5 cm) with the BioWick™ SureLock™ implant. Both performance and safety data will be collected.

Detailed Description

Study Title Efficacy of the BioWick SureLock Implant for the Reattachment of Soft Tissue to Bone in Subjects Undergoing Rotator Cuff Repairs Sponsor Cayenne Medical, Inc., a Zimmer Biomet company Study Design The study is a prospective, non-randomized, open-label, single-arm study that includes both preoperative assessments and follow-up assessments at 3 months, 6 months, and 12 months. Clinical Phase Postmarket Number of Sites Up to ten sites in the U.S. Study Duration per Subject Subjects will be enrolled in the study for up to 12 months. Primary Objective The primary objective of this study is to assess survivorship (lack of reoperation/device removal) with the use of the BioWick SureLock implant. Secondary Objective The secondary objectives of this study are: To document the postmarket effectiveness of the BioWick SureLock implant using ASES scores, VR-12 scores, and VAS scores, with the corresponding assessments made at 3 months, 6 months, and 12 months postoperative. To document the postmarket effectiveness of the BioWick SureLock implant using range of motion (ROM) measurements with the corresponding assessments made at 3 months and 6 months postoperative. To document device safety via device-related adverse events reported over the course of the study.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study

Rotator Cuff Tear

7. Study Design

Primary Purpose

Treatment

Study Phase

Not Applicable

Interventional Study Model

Single Group Assignment

Masking

None (Open Label)

Allocation

N/A

Enrollment

71 (Actual)

8. Arms, Groups, and Interventions

Arm Title

BioWick SureLock Implant

Arm Type

Experimental

Arm Description

All subjects are part of a single arm. All subjects received the BioWick SureLock implant.

Intervention Type

Device

Intervention Name(s)

BioWick SureLock Implant

Intervention Description

The BioWick SureLock implant is a device for shoulder and extremity surgery, constructed of Ultra High Molecular Weight Polyethylene Suture. BioWick SureLock is uniquely designed to minimize these risks by avoiding manual tensioning with an inserter mechanism that ensures that the implant is consistently deployed below the cortex.

Primary Outcome Measure Information:

Title

Number of Participants Not Requiring Removal or Reoperation of the Implant

Description

The primary endpoint of this study is survivorship (lack of reoperation/device removal) at 12 months postoperative. Implant survivorship for each subject was determined by whether the subject underwent a revision or reoperation of the study device. Survivorship was assessed using a Kaplan-Meier analysis. Possible scores range from 0% (lowest survivorship) to 100% (highest survivorship).

Time Frame

12 months

Secondary Outcome Measure Information:

Title

Number of Participants Not Requiring Removal or Reoperation of the Implant

Description

Implant survivorship (lack of reoperation/device removal) at 3 months and 6 months postoperative. Implant survivorship for each subject was determined by whether the subject underwent a revision or reoperation of the study device. Survivorship was assessed using a Kaplan-Meier analysis. Possible scores range from 0% (lowest survivorship) to 100% (highest survivorship).

Time Frame

3 months, 6 months

Title

American Shoulder and Elbow Surgeons (ASES) Patient Self-Evaluation Score

Description

Pain and function as measured by the American Society of Shoulder and Elbow Surgeons (ASES) questionnaire. ASES consists of 3 subcomponent scores including pain, instability, and activities of daily living. The pain score can be 0 to 10 with 0 being no pain and 10 being the worst pain imaginable. The instability score can be 0 to 10 with 0 being no instability and 10 being the worst instability imaginable. The activities of daily living consists of 10 questions with ordinal responses of 0, 1, 2, and 3 with 3 involving no limitation and 0 is unable to do. The 3 subcomponents combine to make the overall ASES score which can range from 0 to 100 with 0 being the worst possible score and 100 being the best.

Time Frame